Prosecution Insights
Last updated: May 29, 2026
Application No. 18/418,800

TETRADENTATE PLATINUM AND PALLADIUM COMPLEX EMITTERS CONTAINING PHENYL-PYRAZOLE AND ITS ANALOGUES

Non-Final OA §112
Filed
Jan 22, 2024
Priority
Jan 07, 2014 — provisional 61/924,462 +3 more
Examiner
AULAKH, CHARANJIT
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Arizona Board of Regents
OA Round
5 (Non-Final)
81%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
65%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
1422 granted / 1758 resolved
+20.9% vs TC avg
Minimal -16% lift
Without
With
+-15.6%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
46 currently pending
Career history
1800
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
18.5%
-21.5% vs TC avg
§102
21.4%
-18.6% vs TC avg
§112
27.8%
-12.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1758 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . According to paper filed on March 3, 2026, the applicants have filed RCE. The applicants have also amended claims 1, 7, 10-12 and 24. Claims 1-5, 7-8, 10-16, 18, 20-21 and 24 are pending in the application. Claims 15-16 remain withdrawn as being directed to non-elected subject matter. Response to Arguments Applicant’s arguments, see paper, filed March 3, 2026, with respect to claims 1-5, 7-8, 10-14, 18, 20-21 and 24 have been fully considered and are persuasive regarding indefiniteness rejection, written description rejection and Improper Markush group rejection. Therefore, all rejections are withdrawn. NEW GROUNDS OF REJECTION Claim Rejections - 35 USC § 112 5. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-5, 7-8, 10-11, 13-14, 18, 20-21 and 24 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In independent claim 1, variable L2 represents phenyl group only. However, the value of variable V2 is defined to represent either C or N. Therefore, it is not clear how the variable L2 can represent phenyl group when variable V2 represents N. Claim 7 depends upon claim 1. In claim 7, the values of variables Y5-Y8 are defined to represent either C or N. However, according to amended claim 1, the value of variable L4 represents 5-membered heteroaryl ring containing two N only. Therefore, claim 7 lacks antecedent basis when all variables Y5-Y8 represent C or N or only one or two of Y5-Y8 represent C. Claim 11 recites the limitation "more than one double bond (dotted lines) for variable L1" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 21 recites the limitation "more than one double bond (dotted lines) for variable L1" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Allowable Subject Matter Claim 12 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARANJIT AULAKH whose telephone number is (571)272-0678. The examiner can normally be reached Monday-Friday 7:00-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARANJIT AULAKH/ Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Show 4 earlier events
Jul 01, 2025
Request for Continued Examination
Jul 08, 2025
Response after Non-Final Action
Jul 30, 2025
Non-Final Rejection mailed — §112
Oct 30, 2025
Response Filed
Dec 03, 2025
Final Rejection mailed — §112
Mar 03, 2026
Request for Continued Examination
Mar 10, 2026
Response after Non-Final Action
Mar 26, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12636278
HDAC6-INHIBITED HUMAN REGULATORY T CELLS
3y 10m to grant Granted May 26, 2026
Patent 12637464
TETRACYCLIC COMPOUNDS FOR TREATING BRAIN DISORDERS
2y 7m to grant Granted May 26, 2026
Patent 12629337
DAPTOMYCIN FORMULATION
3y 10m to grant Granted May 19, 2026
Patent 12625144
CHEMOSELECTIVE SENSITIVITY BOOSTER FOR TAGGING A PEPTIDE, PEPTIDE CONJUGATE, OR SIMILAR REACTIVE MOLECULE
4y 5m to grant Granted May 12, 2026
Patent 12624042
COMPOUND FOR TARGETED DEGRADATION OF BTK AND ANTI-TUMOUR USE THEREOF
3y 0m to grant Granted May 12, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
81%
Grant Probability
65%
With Interview (-15.6%)
2y 0m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1758 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month